IL165067A0 - Thiadiazole and oxadiazole derivatives and pharmaceutical compositions containing the same - Google Patents
Thiadiazole and oxadiazole derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- IL165067A0 IL165067A0 IL16506704A IL16506704A IL165067A0 IL 165067 A0 IL165067 A0 IL 165067A0 IL 16506704 A IL16506704 A IL 16506704A IL 16506704 A IL16506704 A IL 16506704A IL 165067 A0 IL165067 A0 IL 165067A0
- Authority
- IL
- Israel
- Prior art keywords
- thiadiazole
- same
- pharmaceutical compositions
- compositions containing
- oxadiazole derivatives
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 102000015617 Janus Kinases Human genes 0.000 abstract 1
- 108010024121 Janus Kinases Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37818502P | 2002-05-06 | 2002-05-06 | |
| PCT/US2003/014223 WO2004058753A1 (en) | 2002-05-06 | 2003-05-06 | Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL165067A0 true IL165067A0 (en) | 2005-12-18 |
Family
ID=32681783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16506704A IL165067A0 (en) | 2002-05-06 | 2004-11-07 | Thiadiazole and oxadiazole derivatives and pharmaceutical compositions containing the same |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7271179B2 (xx) |
| EP (2) | EP1501829B1 (xx) |
| JP (2) | JP4681302B2 (xx) |
| KR (1) | KR20050006237A (xx) |
| CN (1) | CN1665808A (xx) |
| AT (1) | ATE489384T1 (xx) |
| AU (1) | AU2003299472A1 (xx) |
| CA (1) | CA2485429A1 (xx) |
| DE (1) | DE60335099D1 (xx) |
| IL (1) | IL165067A0 (xx) |
| MX (1) | MXPA04011048A (xx) |
| NO (1) | NO20045282L (xx) |
| RU (1) | RU2004135386A (xx) |
| WO (1) | WO2004058753A1 (xx) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1534286B1 (en) | 2002-07-29 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| DE102004009933A1 (de) * | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Verwendung von Thiadiazolharnstoffderivaten |
| US7388021B2 (en) * | 2004-05-12 | 2008-06-17 | Bristol Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| CA2572331A1 (en) * | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| PT1791830E (pt) | 2004-09-17 | 2011-04-04 | Vertex Pharma | Compostos de diaminotriazole úteis como inibidores de proteína-quinase |
| EA012181B1 (ru) * | 2004-10-18 | 2009-08-28 | Амген, Инк. | Соединения тиадиазола и их применение |
| CA2590294A1 (en) * | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| ATE499370T1 (de) * | 2005-01-19 | 2011-03-15 | Bristol Myers Squibb Co | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| JP5225079B2 (ja) | 2005-06-08 | 2013-07-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| US7816382B2 (en) | 2005-06-27 | 2010-10-19 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition |
| JP2008543972A (ja) * | 2005-06-27 | 2008-12-04 | ブリストル−マイヤーズ スクイブ カンパニー | 血栓症状の治療に有用なｐ２ｙ１受容体のｎ−結合複素環式アンタゴニスト |
| ATE485269T1 (de) * | 2005-06-27 | 2010-11-15 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden |
| US20090054483A1 (en) * | 2005-10-05 | 2009-02-26 | Yves Ducharme | Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis |
| EP1991532B1 (en) | 2006-02-24 | 2017-01-11 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20070213378A1 (en) * | 2006-03-10 | 2007-09-13 | Lymphosign Inc. | Compounds for modulating cell proliferation, compositions and methods related thereto |
| MX2009003673A (es) | 2006-10-04 | 2009-04-22 | Pfizer Prod Inc | Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio. |
| US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| WO2008139845A1 (ja) * | 2007-04-24 | 2008-11-20 | Daiichi Sankyo Company, Limited | 新規アミド誘導体 |
| EP2265607B1 (en) | 2008-02-15 | 2016-12-14 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
| PT2323993E (pt) | 2008-04-16 | 2015-10-12 | Portola Pharm Inc | 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| WO2009131687A2 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| KR101696936B1 (ko) * | 2008-07-10 | 2017-01-16 | 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 | 퀴놀린카르복사미드 유도체를 유효 성분으로 하는 ｓｔａｔ３ 저해제 |
| RU2529019C2 (ru) * | 2009-02-27 | 2014-09-27 | Эмбит Байосайенсиз Корпорейшн | Модулирующие jak киназу хиназолиновые производные и способы их применения |
| US8361962B2 (en) * | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
| US8796320B2 (en) | 2009-12-28 | 2014-08-05 | General Incorporated Association Pharma Valley Project Supporting Organization | 1,3,4-Oxadiazole-2-carboxamide compound |
| KR101483215B1 (ko) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| SG186229A1 (en) | 2010-06-07 | 2013-01-30 | Novomedix Llc | Furanyl compounds and the use thereof |
| EP2397482A1 (en) * | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| CN101891697B (zh) * | 2010-07-02 | 2011-08-31 | 山东大学 | 含1，2，4-噁二唑杂环α，β-不饱和酮类化合物 |
| US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
| MX363551B (es) | 2011-11-23 | 2019-03-27 | Portola Pharmaceuticals Inc Star | Compuestos derivados de pirazina como inhibidores de cinasa. |
| KR101328126B1 (ko) * | 2012-04-10 | 2013-11-08 | 연세대학교 원주산학협력단 | 신규한 옥사디아졸 유도체 및 이의 알레르기 질환의 예방, 개선 또는 치료적 용도 |
| SG10201704095UA (en) | 2012-04-24 | 2017-06-29 | Vertex Pharma | Dna-pk inhibitors |
| CN103382206B (zh) * | 2012-05-04 | 2016-09-28 | 上海恒瑞医药有限公司 | 喹啉或喹唑啉类衍生物、其制备方法及其在医药上的应用 |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| CN104936963B (zh) * | 2012-11-20 | 2017-11-28 | 普罗齐纳斯有限公司 | 作为蛋白激酶抑制剂的硫醚衍生物 |
| CL2012003253A1 (es) * | 2012-11-22 | 2013-01-11 | Univ Concepcion | Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico. |
| LT2970218T (lt) | 2013-03-12 | 2019-03-12 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitoriai |
| RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| AU2014353006B2 (en) | 2013-11-20 | 2019-04-04 | Signalchem Life Sciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
| JP6269942B2 (ja) * | 2014-02-20 | 2018-01-31 | 国立研究開発法人理化学研究所 | ｐ３８ＭＡＰキナーゼγおよび／またはδ阻害剤 |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
| WO2018160944A1 (en) * | 2017-03-03 | 2018-09-07 | Progenra, Inc. | Azole compounds as ubiquitin-specific protease usp7 inhibitors |
| CN108148058B (zh) * | 2018-02-08 | 2021-03-16 | 中国人民解放军第四军医大学 | 一种4-(2-巯基噻二唑)取代的嘧啶衍生物其制备方法及应用 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN118201924A (zh) * | 2021-11-08 | 2024-06-14 | 万特斯治疗美国公司 | 杂环化合物及其用途 |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| WO1999031096A1 (en) * | 1997-12-18 | 1999-06-24 | Shaman Pharmaceuticals, Inc. | Piperazine derivatives useful as hypoglycemic agents |
| WO1999062908A2 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US6486158B1 (en) * | 1998-08-14 | 2002-11-26 | Cell Pathways, Inc. | [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia |
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| WO2000075145A1 (en) * | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| JP2001354658A (ja) * | 2000-06-15 | 2001-12-25 | Taisho Pharmaceut Co Ltd | ヒドロキシホルムアミジン化合物及びその塩並びにそれらを含む医薬 |
| EE200200715A (et) | 2000-06-28 | 2004-08-16 | Astrazeneca Ab | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena |
-
2003
- 2003-05-06 DE DE60335099T patent/DE60335099D1/de not_active Expired - Lifetime
- 2003-05-06 AT AT03799762T patent/ATE489384T1/de not_active IP Right Cessation
- 2003-05-06 MX MXPA04011048A patent/MXPA04011048A/es unknown
- 2003-05-06 EP EP03799762A patent/EP1501829B1/en not_active Expired - Lifetime
- 2003-05-06 KR KR10-2004-7017933A patent/KR20050006237A/ko not_active Application Discontinuation
- 2003-05-06 US US10/430,805 patent/US7271179B2/en not_active Expired - Fee Related
- 2003-05-06 RU RU2004135386/04A patent/RU2004135386A/ru not_active Application Discontinuation
- 2003-05-06 CA CA002485429A patent/CA2485429A1/en not_active Abandoned
- 2003-05-06 WO PCT/US2003/014223 patent/WO2004058753A1/en active Application Filing
- 2003-05-06 JP JP2004563181A patent/JP4681302B2/ja not_active Expired - Fee Related
- 2003-05-06 AU AU2003299472A patent/AU2003299472A1/en not_active Withdrawn
- 2003-05-06 EP EP10182153A patent/EP2316834A1/en not_active Withdrawn
- 2003-05-06 CN CN038159546A patent/CN1665808A/zh active Pending
-
2004
- 2004-11-07 IL IL16506704A patent/IL165067A0/xx unknown
- 2004-12-02 NO NO20045282A patent/NO20045282L/no not_active Application Discontinuation
-
2010
- 2010-04-26 JP JP2010101525A patent/JP2010159306A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2485429A1 (en) | 2004-07-15 |
| KR20050006237A (ko) | 2005-01-15 |
| RU2004135386A (ru) | 2005-07-20 |
| EP1501829A1 (en) | 2005-02-02 |
| US20040038992A1 (en) | 2004-02-26 |
| EP2316834A1 (en) | 2011-05-04 |
| CN1665808A (zh) | 2005-09-07 |
| JP4681302B2 (ja) | 2011-05-11 |
| WO2004058753A1 (en) | 2004-07-15 |
| US7271179B2 (en) | 2007-09-18 |
| EP1501829B1 (en) | 2010-11-24 |
| WO2004058753A8 (en) | 2005-06-16 |
| AU2003299472A1 (en) | 2004-07-22 |
| JP2010159306A (ja) | 2010-07-22 |
| DE60335099D1 (de) | 2011-01-05 |
| MXPA04011048A (es) | 2005-02-17 |
| NO20045282L (no) | 2005-02-07 |
| ATE489384T1 (de) | 2010-12-15 |
| JP2006513192A (ja) | 2006-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL165067A0 (en) | Thiadiazole and oxadiazole derivatives and pharmaceutical compositions containing the same | |
| YU53700A (sh) | Biciklo(2.2.1.) heptani i srodna jedinjenja | |
| EP1259487B8 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
| YU73300A (sh) | Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije | |
| UA83243C2 (ru) | Соединения, которые ингибируют натриезависимый переносчик глюкозы | |
| HUP0300497A2 (hu) | Humán foszfatidilinozit-3-kináz-delta inhibitorok és alkalmazásuk | |
| ATE247654T1 (de) | Neue heterozyklische verbindungen | |
| NO913750D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater. | |
| NZ506574A (en) | Cyclic amino derivative having a sulphinyl, sulphonyl or disulphanyl group useful in the treatment of thrombosis or embolism | |
| MXPA04005990A (es) | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1. | |
| DK289888D0 (da) | 2-substitueret-e-kondenserede oe1,2,4,aatriazolooe1,5-caapyrimidiner, farmaceutiske praeparater og anvendelser deraf | |
| NZ512658A (en) | Heterocyclic-substituted diphenylurea derivatives and pharmaceutical compositions containing them | |
| DE3572978D1 (en) | Piperazine compound as paf-antagonist | |
| EA200000614A1 (ru) | 2,3-замещенные соединения индола в качестве ингибиторов сох-2 | |
| HUT70194A (en) | Quinoline- or quinazoline derivatives, process for producing them and pharmaceutical compositions containing them | |
| DE60105610D1 (en) | Pyrazinonderivate | |
| EP0808839A4 (en) | EPOXYSUCCINAMIDE DERIVATIVES OR THEIR SALTS AND MEDICATIONS CONTAINING THEM | |
| EP0656355A4 (en) | BIPHENYLMETHANE DERIVATIVE AND MEDICINE CONTAINING THE SAME. | |
| CA2491943A1 (en) | Epothilone derivatives for the treatment of cancer | |
| DE69523819D1 (de) | Quinolin-Derivate und diese enthaltende pharmazeutische Zusammensetzungen | |
| HUT40658A (en) | Process for producing benzo/c/-1,5-naphtiridin derivatives and pharmaceutical compositions containing them as active agents | |
| EA200200379A3 (ru) | Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции | |
| JO1648B1 (en) | Nitrogen compounds |